An Evaluation of the Safety and Pharmacokinetics of Tavaborole Topical Solution for the Treatment of Fungal Disease of the Toenail in Children and Adolescents

Onychomycosis Clinical Trial

Official title:

An Open-label Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Kerydin (Registered) (Tavaborole) Topical Solution, 5% In The Treatment Of Onychomycosis Of The Toenail In Pediatric Subjects Ages 6 To 16 Years And 11 Months

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03405818
• Other study ID #: TAV-ONYC-401
• Secondary ID: C3371003
• Status: Completed
• Phase: Phase 4
• First received: January 3, 2018
• Last updated: March 19, 2018
• Start date: October 22, 2015
• Est. completion date: July 27, 2017

Study information

• Verified date: March 2018
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This was an open-label study to evaluate the safety and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (a fungal infection) of the toenail in children and adolescents (ages 6 to 16 years).

Following confirmation of eligibility, including laboratory evidence of a fungal organism in the toenail, tavaborole topical solution was applied once daily to all affected toenails for a 48-week treatment period.

Clinical assessment of the extent of infection and safety assessments were performed periodically throughout the 48-week treatment period, and again at 52 weeks (4 weeks after stopping the treatment).

A subgroup of enrolled subjects applied the topical solution to all 10 toenails and a small area of surrounding skin during the first 28 days. These subjects had blood samples analyzed to evaluate the pharmacokinetics (how the drug moves in the body) of tavaborole topical solution in children and adolescents.

Description:

This was an open-label study to evaluate the safety, tolerability, and pharmacokinetics of tavaborole 5% topical solution in treating distal subungual onychomycosis (DSO) of the toenail in pediatric subjects aged 6 to 16 years and 11 months. An eligible subject had a target great toenail (TGT) with at least 20% involvement, with a positive potassium hydroxide (KOH) wet mount and positive fungal culture for T. rubrum or T. mentagrophytes.

Eligible subjects applied tavaborole 5% topical solution, once daily to all affected toenails (the TGT as well as all other toenails having the clinical characteristics of onychomycosis) throughout the 48 week treatment period.

Subjects were evaluated at Screening, Baseline (Day 1), and at Weeks 2, 4, 8, 16, 24, 32, 40, 48, and 52. Each evaluation included a clinical assessment of the AEs and local tolerability evaluation.

Additional procedures were performed as follows:

• Mycology sampling at Screening, Week 24, and Week 52/early termination (ET);

• Clinical disease severity of the TGT at Screening, Week 24, and Week 52/ET;

• Safety laboratory testing at Baseline, Week 24, and Week 52/ET;

In this study, there was a PK subgroup of evaluable subjects aged 12 to 16 years and 11 months studied under maximal use conditions. Subjects in this maximal use subgroup applied the study drug on all 10 toenails, including up to 2 mm of the surrounding skin, for 28 days. On Day 15, a predose PK sample was collected to assess steady state trough level. On Day 29, the study drug application was done at the study site, and PK samples were collected prior to dosing, as well as 4, 6, 8, and 24 hours postdose on Days 29 to 30.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 55
• Est. completion date: July 27, 2017
• Est. primary completion date: July 27, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 72 Months to 203 Months

Eligibility

Inclusion Criteria:

• males or females, ages >/= 6 years and </= 16 years and 11 months

• clinical diagnosis of distal subungual onychomycosis affecting at least 20% of one of the great toenails (target nail); and with positive KOH and positive culture for T. rubrum or T. mentagrophytes from either great toenail

Exclusion Criteria:

• the target toenail has proximal subungual onychomycosis, onychomycosis involving the nail lunula, superficial white onychomycosis, dermatophytoma, exclusively lateral disease, or yellow or brown spikes, or has co-infection with certain fungi or molds

• anatomic abnormalities of the toes or toenail

• current or past history of chronic moccasin-type tinea pedis

• current or past history of psoriasis or lichen planus

• history of significant chronic fungal disease (other than onychomycosis)

• diabetes

• immunodeficiency

Related Conditions & MeSH terms

• Onychomycosis
• Tinea Unguium

Intervention

Drug:
• Tavaborole 5% Topical Solution
topical solution for application to toenails

Locations

Country	Name	City	State
United States	University Hospital, SUNY Downstate Medical Center	Brooklyn	New York
United States	PI Coor Clinical Research, LLC	Burke	Virginia
United States	Cyn3rgy Research	Gresham	Oregon
United States	West Houston Clinical Research Services LLC	Houston	Texas
United States	Madera Family Medical Group	Madera	California
United States	Skin Specialty Dermatology	New York	New York
United States	Stanford University School of Medicine	Palo Alto	California
United States	Oregon Dermatology & Research Center	Portland	Oregon
United States	Texas Dermatology and Laser Specialists	San Antonio	Texas
United States	Doctors Research Network	South Miami	Florida
United States	MedStar Health Research Institute - MedStar Georgetown University Hospital	Washington	District of Columbia
United States	Jordan Valley Dermatology Center	West Jordan	Utah

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Local Tolerability Reactions by Severity	Local tolerability reactions consisted of burning/stinging, induration/edema, oozing and crusting, pruritus, erythema, and scaling. Here 0 indicates None, 1 (Mild), 2 (Moderate) and 3 (severe). Grading details are as follows: Burning/Stinging (0: no stinging/burning, 1: slight warm, 2: definite warm, 3: hot); Induration/Edema (0: no elevation, 1: barely perceptible elevation, 2: clearly perceptible elevation but not extensive, 3: marked and extensive elevation); Oozing and Crusting (0: absent, 1: faint signs of oozing, 2: definite oozing, 3: marked and extensive oozing); Pruritus (0: no pruritus, 1: occasional, slight itching, 2: constant itching which is not disturbing sleep, 3: severe bothersome itching/scratching which is disturbing sleep); Erythema (0: no redness present, 1: faintly detectable erythema; very light pink, 2: dull red, 3: deep/dark red); Scaling (0: no scaling, 1: barely perceptible shedding, 2: obvious but not profuse scaling, 3: heavy scale production).	Baseline up to Week 52
Primary	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pre-treatment state. AEs included both serious and non-serious AEs.	Baseline up to 28 days after last dose of study drug (up to Week 52)
Primary	Number of Participants With Adverse Events (AEs) By Severity	An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs were classified as mild, moderate and severe based on severity assessment by investigator and defined as: Mild = symptoms barely noticeable to the participant or does not make the participant uncomfortable; moderate = symptoms of a sufficient severity to make the participant uncomfortable; severe = symptoms of a sufficient severity to cause the participant severe discomfort.	Baseline up to 28 days after last dose of study drug (up to Week 52)
Primary	Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Hematology Parameters (Leukocytes: Basophils, Eosinophils, Lymphocytes, Monocytes and Neutrophils) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Hematology Parameter (Hematocrit) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Hematology Parameter (Hematocrit) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Hematology Parameter (Erythrocytes) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Hematology Parameter (Erythrocytes) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Hematology Parameters (Hemoglobin) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Hematology Parameters (Hemoglobin) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Hematology Parameters (Leukocytes and Platelets) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Chemistry Parameters (Alanine Aminotransferase, Alkaline Phosphatase and Aspartate Aminotransferase) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Chemistry Parameters (Albumin and Protein) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Chemistry Parameters (Bilirubin, Creatinine, Glucose [Non-fasting] and Urea Nitrogen) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Chemistry Parameters (Potassium and Sodium) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Vital Sign (Blood Pressure) at Week 24		Baseline, Week 24
Primary	Change From Baseline in Vital Sign (Blood Pressure) at Week 52		Baseline, Week 52
Primary	Change From Baseline in Vital Sign (Pulse Rate) at Week 24	Pulse rate was defined as the number of pulsations noted in a peripheral artery per minute after participant rested supine for 5 minutes.	Baseline, Week 24
Primary	Change From Baseline in Vital Sign (Pulse Rate) at Week 52	Pulse rate was defined as the number of pulsations noted in a peripheral artery per minute after participant rested supine for 5 minutes.	Baseline, Week 52
Primary	Change From Baseline in Vital Sign (Respiratory Rate) at Week 24	Respiratory rate was defined as the number of inspirations per minute.	Baseline, Week 24
Primary	Change From Baseline in Vital Sign (Respiratory Rate) at Week 52	Respiratory rate was defined as the number of inspirations per minute.	Baseline, Week 52
Primary	Percentage of Participants With Complete Cure of Target Great Toenail (TGT) at Week 52	Complete cure was defined as completely clear nail, negative fungal culture and negative potassium hydroxide (KOH) wet mount.	Week 52
Secondary	Maximum Observed Plasma Concentration (Cmax) of Tavaborole		Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Time to Maximum Observed Plasma Concentration (Tmax) of Tavaborole		Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Area Under the Plasma Concentration-Time Curve From Hour Zero to Hour 24 (AUC24) of Tavaborole	AUC24 was defined as the area under the plasma concentration-time curve from hour 0 to hour 24. AUC24 was calculated using the linear trapezoidal rule.	Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Area Under the Plasma Concentration-Time Curve Extrapolated to Infinity (AUCinf) of Tavaborole		Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Elimination Rate Constant of Tavaborole	Elimination rate constant was defined as the rate at which a drug was removed from the body.	Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Elimination Half-Life of Tavaborole	Elimination half-life (t1/2) was defined as the time required for the body to eliminate half of the drug than its original concentration.	Pre-dose, 4, 6, 8, 24 hours post-dose on Day 29
Secondary	Percentage of Participants With Almost Complete Cure of Target Great Toenail (TGT) at Week 24 and 52	Almost complete cure was defined as almost clear nail and negative mycology (negative mycology was defined as negative fungal culture and negative KOH wet mount).	Week 24, 52
Secondary	Percentage of Participants With Clinical Efficacy of Target Great Toenail (TGT) at Week 24 and 52	Clinical efficacy target great toenail (TGT) was defined as completely clear nail or almost clear nail.	Week 24, 52
Secondary	Percentage of Participants With Mycological Cure of Target Great Toenail (TGT) at Week 24 and 52	Mycological cure was defined as negative mycology of the TGT. Negative mycology was defined as negative fungal culture and negative potassium hydroxide (KOH) wet mount. Participants with only one result for either fungal culture or KOH were excluded from this analysis.	Week 24, 52
Secondary	Percentage of Participants With Negative Fungal Culture of the Target Great Toenail (TGT) at Weeks 24 and 52		Week 24, 52